For sponsors running cardiometabolic programs, early clinical development often hinges on one question: can a site deliver predictable recruitment, high participant retention, and clean, decision-grade data—on time and to protocol?
Yet many trial teams still contend with familiar operational risks: finding enough eligible participants, sustaining engagement to minimise drop-out, and maintaining robust medical and scientific oversight to protect data integrity and participant safety. In early phase studies, these challenges are amplified by tight timelines, complex visit schedules, and intensive assessments.
According to GlobalData, around 80% of clinical trials fail to recruit and retain enough patients, leading to delays and increased costs[i], while only about 36% of early-phase clinical trials meet their planned recruitment targets[ii]. In addition, average dropout rates in traditional clinical trials are around 30%, with participants frequently discontinuing due to complex protocols, logistical burdens such as travel, unclear information about participation, and inadequate reimbursement[iii].
As a result, retention remains a core problem even when enrolment targets are met, threatening trial objectives and underlining the need for robust, well-designed engagement strategies. Regulatory hurdles and protocol amendments can also add delays, with inadequate data integrity, patient safety issues, and insufficient monitoring, all potentially compromising trial validity.
Against this backdrop, site performance is critical. Top-performing sites do not sidestep complex protocols. Instead, they invest in advanced recruitment, retention, and oversight approaches that support stronger data quality and more meaningful cardiometabolic trial outcomes.
Specialists in clinical research for early phase trials
Nucleus Network is a specialised clinical research organisation focusing on the design and conduct of clinical pharmacology trials across its four clinical units, with particular expertise in Phase 1 through 2a execution and complex, data-intensive protocols in cardiometabolic disease.
Its strength is helping sponsors de-risk Phase 1 and early clinical development by pairing over 30 years of experience with high-performing recruitment operations, rigorous PI-led oversight and on-site technical capability. The result is faster, more reliable execution for complex cardiometabolic protocols—without compromising quality.
The company’s Minneapolis site is a flagship example of how disciplined recruitment, participant management, and scientific oversight translate into consistent, decision-grade outcomes for sponsors.
The Rivus RIV-HU6-203 and Response Pharma RDX-002-024-011 studies are cutting-edge cardiometabolic trials targeting obesity, liver fat reduction, and metabolic dysfunction. RIV-HU6-203 was a 61-day, randomised, double-blind, placebo-controlled trial of HU6 in participants with elevated liver fat and high BMI. RDX-002-024-011 focused on patients who wanted to discontinue their GLP-1 receptor agonists use the investigational product to prevent weight gain. It used advanced cardiometabolic endpoints – postprandial triglyceride, glucose, and insulin AUC; insulin sensitivity; lipid profiles; and body weight/composition – using a structured two-part protocol with rigorous follow-up.
Both studies demanded intensive oversight, specialised testing, and careful participant management—making them strong benchmarks for sponsor-relevant performance measures such as screening efficiency, enrolment velocity, protocol adherence, retention, and quality of complex endpoint data.
A cardiometabolic study with multiple complexities – Rivus: RIV-HU6-203
RIV-HU6-203 was a complex cardiometabolic study characterised by stringent inclusion criteria and advanced metabolic endpoints. The Minneapolis site encountered an 84% screen-fail rate, underscoring the difficulty of identifying suitable participants under such tight parameters. To ensure they could still achieve the enrolment targets despite the high screen fail rate, the team refined its recruitment strategy, leading to a marked increase in screening. Over 16 weeks, 506 participants were screened, and 80 were ultimately randomised. This is a strong result given the complexity of the eligibility requirements and the demands of the study design.
Overcoming challenges with clinical trial recruitment – Response Pharma: RDX-002-024-011
RDX-002-024-011 was conducted under notably challenging enrolment conditions, including holiday periods that traditionally slow recruitment. Additionally, the site needed to identify patients interested in discontinuing their GLP-1 RA, but before they had stopped their treatment. To mitigate this, the Minneapolis site deployed precision-targeted digital advertising supported by AI-driven outreach, extending beyond conventional referral pathways. This approach enabled the team to reach and engage appropriate candidates at scale, resulting in the successful enrolment of 68 participants in just 14 weeks, despite the seasonal constraints that typically hinder cardiometabolic trial recruitment.
These two studies show the strength of the Minneapolis site as a model for complex cardiometabolic trials, built on a deliberate strategy of targeted marketing and recruitment, strong participant engagement, and rigorous scientific oversight.
For example, to overcome recruitment challenges, the site used AI-driven ‘look-alike’ audiences based on short screening questionnaires. If a patient qualified based on the questionnaire, the AI then targets advertisement as individual who have similar characteristics. Both targeting and engagement were boosted with increased screening efficiency across diverse study populations. This approach is now a cornerstone of the site’s recruitment strategy, supporting scalable, data-driven enrolment across multiple therapeutic areas.
Ensuring compliance, retention, and oversight for clinical trial data
High-quality data depends on participants remaining engaged and compliant with the protocol. At the Minneapolis site, Recruitment Officers introduced study commitments during initial contact, with the Principal Investigator (PI) and medical team reinforcing expectations and study rationale at screening, as well as regular reminders during participation. Using this structured approach, the site achieved over 96% compliance across key activities, such as diaries, and more than 94% retention across both trials and the RDX-002-024-011 open-label extension.
The highly experienced PI remained actively involved throughout all phases of the trials, ensuring adherence to regulatory standards, consistency in complex assessments and endpoints, and effective oversight of safety, data quality and protocol compliance.
In parallel, the site demonstrated substantial technical capability in complex testing and advanced imaging, including insulin sensitivity testing for detailed metabolic profiling, MRI-PDFF to quantify liver fat, and Fibroscan® to assess liver stiffness. This combination of experienced leadership and sophisticated diagnostic capacity enabled the team to deliver demanding cardiometabolic protocols with a high degree of confidence and precision.
Impact and performance of the cardiometabolic studies
Quantitative performance metrics reinforce this picture. In RIV-HU6-203, the site screened 506 participants, enrolled and randomised 80, and achieved a retention rate of 94% with a compliance rate of 97%. Alongside this, 128 MRI, 216 Fibroscan, and 109 ophthalmologic imaging procedures were performed. In RDX-002-024-011, 117 participants were screened and 68 enrolled, with retention reaching 98%, and 117 body composition imaging procedures were performed.
This robust and complete data set helped both trials achieve primary and secondary endpoints, demonstrating meaningful reductions in liver fat and body weight, alongside improvements in cardiometabolic risk markers.
These case studies highlight the Minneapolis site’s strengths in patient recruitment, complex testing, advanced imaging, and long‑term participant management in cardiometabolic research. Furthermore, these studies demonstrate how innovative recruitment, participant‑centred engagement, and rigorous scientific oversight all position Nucleus Network Minneapolis as a trusted partner for reliable, clinically relevant data.
To discuss how Nucleus Network can support your Phase 1 or early clinical development program—particularly for complex cardiometabolic protocols—download the report below or contact our team.
[i] GlobalData: Artificial Intelligence in Healthcare, September 2024
[ii] GlobalData: Artificial Intelligence in Healthcare, November 2025
[iii] GlobalData: Artificial Intelligence in Healthcare, September 2024
